Ofloxacin: New applications for the prevention of urinary tract infections in renal graft recipients

Transplant Infectious Disease

Volumn 13, Issue 4, 2011, Pages 344-352

  Rafat, C ^a   Vimont, S ^a   Ancel, P Y ^a   Xu Dubois, Y C ^a   Mesnard, L ^a   Ouali, N ^a   Denis, M ^a   Vandewalle, A ^b,c   Rondeau, E ^a,d   Hertig, A ^a,d  

^a HÔPITAL TENON   (France)

^b CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d SORBONNE UNIVERSITÉ   (France)

Author keywords

Antibioprophylaxis; Bacterial drug resistance; Fluoroquinolones; Ofloxacin; Pyelonephritis; Renal transplantation; Urinary tract infection

Indexed keywords

ATOVAQUONE; CIPROFLOXACIN; COTRIMOXAZOLE; OFLOXACIN; SULFAMETHOXAZOLE; TRIMETHOPRIM;

ACUTE PYELONEPHRITIS; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; CONFIDENCE INTERVAL; FEMALE; GRAFT RECIPIENT; HOSPITAL DEPARTMENT; HUMAN; INCIDENCE; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; LEGIONELLA PNEUMOPHILA; LEGIONNAIRE DISEASE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PNEUMOCYSTOSIS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RISK; URINARY TRACT INFECTION;

ACUTE DISEASE; ADULT; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INCIDENCE; KIDNEY TRANSPLANTATION; LEGIONELLA PNEUMOPHILA; LEGIONNAIRES' DISEASE; MALE; MIDDLE AGED; OFLOXACIN; PYELONEPHRITIS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; URINARY TRACT INFECTIONS;

EID: 79961209984     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2011.00602.x     Document Type: Article

References (41)

1. Alangaden GJ, Thyagarajan R, Gruber SA, et al. Infectious complications after kidney transplantation: current epidemiology and associated risk factors. Clin Transplant 2006; 20 (4): 401-409.
2. de Souza RM, Olsburgh J. Urinary tract infection in the renal transplant patient. Nat Clin Pract Nephrol 2008; 4 (5): 252-264.
3. Reis MA, Costa RS, Ferraz AS. Causes of death in renal transplant recipients: a study of 102 autopsies from 1968 to 1991. J R Soc Med 1995; 88 (1): 24-27.
4. Abbott KC, Swanson SJ, Richter ER, et al. Late urinary tract infection after renal transplantation in the United States. Am J Kidney Dis 2004; 44 (2): 353-362.
5. Chuang P, Parikh CR, Langone A. Urinary tract infections after renal transplantation: a retrospective review at two US transplant centers. Clin Transplant 2005; 19 (2): 230-235.
6. Pelle G, Vimont S, Levy PP, et al. Acute pyelonephritis represents a risk factor impairing long-term kidney graft function. Am J Transplant 2007; 7 (4): 899-907.
7. Giral M, Pascuariello G, Karam G, et al. Acute graft pyelonephritis and long-term kidney allograft outcome. Kidney Int 2002; 61 (5): 1880-1886.
8. Audard V, Amor M, Desvaux D, et al. Acute graft pyelonephritis: a potential cause of acute rejection in renal transplant. Transplantation 2005; 80 (8): 1128-1130.
9. Peterson PK, Ferguson R, Fryd DS, Balfour HH, Rynasiewicz J, Simmons RL. Infectious diseases in hospitalized renal transplant recipients: a prospective study of a complex and evolving problem. Medicine (Baltimore) 1982; 61 (6): 360-372.
10. Senger SS, Arslan H, Azap OK, Timurkaynak F, Cagir U, Haberal M. Urinary tract infections in renal transplant recipients. Transplant Proc 2007; 39 (4): 1016-1017.
11. Onrust SV, Lamb HM, Balfour JA. Ofloxacin. A reappraisal of its use in the management of genitourinary tract infections. Drugs 1998; 56 (5): 895-928.
12. Vogt P, Schorn T, Frei U. Ofloxacin in the treatment of urinary tract infection in renal transplant recipients. Infection 1988; 16 (3): 175-178.
13. Bucaneve G, Micozzi A, Menichetti F, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005; 353 (10): 977-987.
14. Liang RH, Yung RW, Chan TK, et al. Ofloxacin versus co-trimoxazole for prevention of infection in neutropenic patients following cytotoxic chemotherapy. Antimicrob Agents Chemother 1990; 34 (2): 215-218.
15. Baum HV, Franz U, Geiss HK. Prevalence of ciprofloxacin-resistant Escherichia coli in hematologic-oncologic patients. Infection 2000; 28 (5): 278-281.
16. Carratala J, Fernandez-Sevilla A, Tubau F, Dominguez MA, Gudiol F. Emergence of fluoroquinolone-resistant Escherichia coli in fecal flora of cancer patients receiving norfloxacin prophylaxis. Antimicrob Agents Chemother 1996; 40 (2): 503-505.
17. Kool JL, Bergmire-Sweat D, Butler JC, et al. Hospital characteristics associated with colonization of water systems by Legionella and risk of nosocomial Legionnaires' disease: a cohort study of 15 hospitals. Infect Control Hosp Epidemiol 1999; 20 (12): 798-805.
18. Sabria M, Yu VL. Hospital-acquired legionellosis: solutions for a preventable infection. Lancet Infect Dis 2002; 2 (6): 368-373.
19. Pedro-Botet ML, Sabria-Leal M, Sopena N, et al. Role of immunosuppression in the evolution of Legionnaires' disease. Clin Infect Dis 1998; 26 (1): 14-19.
20. Wynckel A, Toupance O, Melin JP, et al. [Treatment of legionellosis with ofloxacin in kidney transplanted patients Lack of interaction with cyclosporin A]. Presse Med 1991; 20 (7): 291-293.
21. Capone D, Tarantino G, Polichetti G, et al. Absence of pharmacokinetic interference of moxifloxacin on cyclosporine and tacrolimus in kidney transplant recipients. J Clin Pharmacol 2010; 50 (5): 576-580.
22. Falagas ME, Koletsi PK, Bliziotis IA. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med Microbiol 2006; 55 (Part 12): 1619-1629.
23. Dubois V, Arpin C, Melon M, et al. Nosocomial outbreak due to a multiresistant strain of Pseudomonas aeruginosa P12: efficacy of cefepime-amikacin therapy and analysis of beta-lactam resistance. J Clin Microbiol 2001; 39 (6): 2072-2078.
24. Giamarellos-Bourboulis EJ, Grecka P, Dionyssiou-Asteriou A, Giamarellou H. Impact of n-6 polyunsaturated fatty acids on growth of multidrug-resistant Pseudomonas aeruginosa: interactions with amikacin and ceftazidime. Antimicrob Agents Chemother 2000; 44 (8): 2187-2189.
25. Hsueh PR, Tseng SP, Teng LJ, Ho SW. Pan-drug-resistant Pseudomonas aeruginosa causing nosocomial infection at a university hospital in Taiwan. Clin Microbiol Infect 2005; 11 (8): 670-673.
26. Leffler H, Svanborg-Eden C. Glycolipid receptors for uropathogenic Escherichia coli on human erythrocytes and uroepithelial cells. Infect Immun 1981; 34 (3): 920-929.
27. Lund B, Lindberg F, Marklund BI, Normark S. The PapG protein is the alpha-D-galactopyranosyl-(1-4)-beta-D-galactopyranose-binding adhesin of uropathogenic Escherichia coli. Proc Natl Acad Sci U S A 1987; 84 (16): 5898-5902.
28. Mulvey MA, Schilling JD, Martinez JJ, Hultgren SJ. Bad bugs and beleaguered bladders: interplay between uropathogenic Escherichia coli and innate host defenses. Proc Natl Acad Sci U S A 2000; 97 (16): 8829-8835.
29. Jantunen ME, Saxen H, Salo E, Siitonen A. Recurrent urinary tract infections in infancy: relapses or reinfections? J Infect Dis 2002; 185 (3): 375-379.
30. Lo Bue AM, Geremia E, Castagna C, Chisari G, Nicoletti G. Sub-MIC ciprofloxacin effect on fimbrial production by uropathogenic Escherichia coli strains. J Chemother 1999; 11 (5): 357-362.
31. Baskin H, Dogan Y, Bahar IH, Yulug N. Effect of subminimal inhibitory concentrations of three fluoroquinolones on adherence of uropathogenic strains of Escherichia coli. Int J Antimicrob Agents 2002; 19 (1): 79-82.
32. Reid G, Habash M, Vachon D, Denstedt J, Riddell J, Beheshti M. Oral fluoroquinolone therapy results in drug adsorption on ureteral stents and prevention of biofilm formation. Int J Antimicrob Agents 2001; 17 (4): 317; discussion 319-320.
33. Wollin TA, Tieszer C, Riddell JV, Denstedt JD, Reid G. Bacterial biofilm formation, encrustation, and antibiotic adsorption to ureteral stents indwelling in humans. J Endourol 1998; 12 (2): 101-111.
34. Kamath NS, John GT, Neelakantan N, Kirubakaran MG, Jacob CK. Acute graft pyelonephritis following renal transplantation. Transpl Infect Dis 2006; 8 (3): 140-147.
35. Livermore DM, James D, Reacher M, et al. Trends in fluoroquinolone (ciprofloxacin) resistance in enterobacteriaceae from bacteremias, England and Wales, 1990-1999. Emerg Infect Dis 2002; 8 (5): 473-478.
36. Al-Hasan MN, Razonable RR, Eckel-Passow JE, Baddour LM. Incidence rate and outcome of Gram-negative bloodstream infection in solid organ transplant recipients. Am J Transplant 2009; 9 (4): 835-843.
37. Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008; 8 (3): 159-166.
38. Paterson DL. "Collateral damage" from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis 2004; 38 (Suppl. 4): S341-S345.
39. Campillo B, Dupeyron C, Richardet JP. Epidemiology of hospital-acquired infections in cirrhotic patients: effect of carriage of methicillin-resistant Staphylococcus aureus and influence of previous antibiotic therapy and norfloxacin prophylaxis. Epidemiol Infect 2001; 127 (3): 443-450.
40. Zervos MJ, Hershberger E, Nicolau DP, et al. Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000. Clin Infect Dis 2003; 37 (12): 1643-1648.
41. Cometta A, Calandra T, Bille J, Glauser MP. Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. N Engl J Med 1994; 330 (17): 1240-1241.